Crewe Advisors’s Caribou Biosciences CRBU Stock Holding History

Crewe Advisors’s Portfolio CRBU Stock Details CRBU Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-24	Closed	-$138	–	952
2023 Q4	$138	Buy	+24	New	+$119	﹤0.01%	396

Other funds holding CRBU

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

EWM

Elmwood Wealth Management Berkeley, California $400M AUM 17.81% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Crewe Advisors's CRBU Position: Q1 2024 in Review

Crewe Advisors sold out of Caribou Biosciences (CRBU) in Q1 2024, closing a stake of 24 shares — an estimated $138 sold.

Crewe Advisors first reported a position in CRBU in Q4 2023 and held it in 1 quarter. The position peaked at $138 in Q4 2023. 151 funds tracked by Wall St. Rank hold CRBU as of Q1 2024.

Crewe Advisors reported no remaining Caribou Biosciences position as of Q1 2024 after selling out during the quarter.
Crewe Advisors sold 24 Caribou Biosciences shares in Q1 2024, an estimated $138.
Crewe Advisors first reported a position in Caribou Biosciences in Q4 2023 and held it in 1 quarter.
Crewe Advisors's Caribou Biosciences position peaked at $138 in Q4 2023.
151 funds tracked by Wall St. Rank held Caribou Biosciences as of Q1 2024.

Based on Crewe Advisors's 13F filing for Q1 2024, filed 14 May 2024.